Bender Jeremy 4

What Happened

• Jeremy Bender, a director of Aura Biosciences, was granted two awards on July 7, 2026: 30,000 restricted stock units (RSUs) and a derivative award covering 60,000 shares. Both awards were reported at $0.00, so no cash changed hands. The RSUs and the derivative award vest in three substantially equal annual installments starting in July 2027 (see footnotes).

Key Details

• Transaction date & price: July 7, 2026; reported price $0.00; transaction code A (award/grant).
• Award amounts: 30,000 RSUs (each represents the right to one share) + 60,000-share derivative award = 90,000 underlying shares granted.
• Vesting: RSUs vest in three equal annual installments beginning July 15, 2027 (F1). The derivative award vests in three equal annual installments beginning July 7, 2027 (F2).
• Shares owned after transaction: not disclosed in the filing.
• Filing timeliness: Reported on 2026-07-08 for a 2026-07-07 transaction — filed promptly, not marked late.
• Note: transaction recorded as awards (compensation), not open-market purchases or sales.

Context

• RSUs convert to actual shares only upon vesting; the derivative award represents a right that vests over time (likely stock options or a similar instrument) and may require exercise to become shares. Neither award resulted in an immediate sale or purchase on the open market. These are typical equity compensation grants subject to continued service and may cause future dilution if and when converted or exercised.